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Lynch syndrome (hereditary nonpolyposis colon
cancer) and adenomatous polyposis syndromes fre-
quently have overlapping clinical features. Current
approaches for molecular genetic testing are often
stepwise, taking a best-candidate gene approach with
testing of additional genes if initial results are nega-
tive. We report a comprehensive assay called ColoSeq
that detects all classes of mutations in Lynch and
polyposis syndrome genes using targeted capture and
massively parallel next-generation sequencing on the
Illumina HiSeq2000 instrument. In blinded speci-
mens and colon cancer cell lines with defined muta-
tions, ColoSeq correctly identified 28/28 (100%)
pathogenic mutations in MLH1, MSH2, MSH6, PMS2,
EPCAM, APC, andMUTYH, including single nucleotide
variants (SNVs), small insertions and deletions, and
large copy number variants. There was 100% reproduc-
ibility ofmutation detection between independent runs.
The assay correctly identified 222 of 224 heterozygous
SNVs (99.4%) in HapMap samples, demonstrating high
sensitivity of calling all variants across each captured
gene. Average coverage was greater than 320 reads per
base pair when the maximum of 96 index samples with
barcodes were pooled. In a specificity study of 19 con-
trol patients without cancer from different ethnic
backgrounds, we did not find any pathogenic muta-tions but detected two variants of uncertain signifi-
cance. ColoSeq offers a powerful, cost-effective means
of genetic testing for Lynch and polyposis syndromes
that eliminates the need for stepwise testing and mul-
tiple follow-up clinical visits. (J Mol Diagn 2012, 14:357-
366; http://dx.doi.org/10.1016/j.jmoldx.2012.03.002)
Defects in mismatch repair (MMR) are responsible for
hereditary nonpolyposis colorectal cancer, also known as
Lynch syndrome. Inherited loss of function mutations in
MLH1, MSH2, MSH6, PMS2, and EPCAM result in a 25%
to 75% lifetime risk of colon cancer and up to a 60%
lifetime risk of endometrial cancer in women.1 The pop-
ulation prevalence of Lynch syndrome is estimated to be
as high as 1 in 440,2 making it the most common inherited
cancer predisposition syndrome. Germline mutations in
APC and MUTYH result in adenomatous polyposis syn-
dromes that are also associated with a very high lifetime
risk of colorectal cancer. Mutations in APC cause familial
adenomatous polyposis, Gardner’s syndrome, Turcot’s
syndrome, and attenuated familial adenomatous polypo-
sis, whereas MUTYH mutations are the cause of auto-
somal recessive MUTYH-associated polyposis syn-
drome.3 Even with clinical guidelines such as the Revised
Bethesda and Amsterdam II criteria,4 it can be challeng-
ing to distinguish Lynch syndrome from adenomatous
polyposis syndromes on the basis of clinical features,
particularly with regard to attenuated familial adenoma-
tous polyposis and Lynch syndrome, which present at a
similar median age of cancer onset (45 to 60 years),
and with similar numbers of colonic polyps.5,6 Clinicians
are therefore frequently faced with the dilemma of which
gene or genes to test first when ordering expensive ge-
netic testing using standard Sanger sequencing.
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JMD July 2012, Vol. 14, No. 4A complex battery of tumor-based screening tests
have been developed for Lynch syndrome, in part be-
cause of the high cost of conventional germline genetic
testing. These tests include functional assessment of de-
fective MMR genes either by demonstration of genomic
microsatellite instability (MSI) or loss of MLH1, MSH2,
MSH6, or PMS2 protein expression by immunohisto-
chemistry (IHC), BRAF V600E mutational analysis, and
MLH1 promoter hypermethylation analysis (screening al-
gorithms are reviewed in Pritchard and Grady7). Loss of
a specific MMR protein revealed by IHC can be helpful in
suggesting which gene most likely harbors a germline
mutation. MMR proteins are often lost as pairs (MLH1/
PMS2 or MSH2/MSH6) because they function as het-
erodimers. However, mutations in PMS2 and MSH6 are
more likely to result in isolated loss of the corresponding
protein by IHC because they are minor partners in the
heterodimer.8 No tumor-based screening tests are cur-
rently available for polyposis syndromes.
Massively parallel next-generation sequencing tech-
nology has dramatically increased throughput and re-
duced the cost per nucleotide sequenced compared with
traditional Sanger methods, enabling cost-effective se-
quencing of multiple genes simultaneously in the clinical
laboratory setting.9–13 Target enrichment is generally re-
quired to achieve adequate read depth for accurate iden-
tification of the spectrum of mutations, including large
genomic rearrangements, small insertions and deletions
(indels), and SNVs.14 We recently reported a proof-of-
principle study demonstrating the accuracy and feasibil-
ity of solution-based targeted capture and next-genera-
tion sequencing for 21 genes that are associated with
breast and ovarian cancer risk.12 Here we report the
validation results of ColoSeq, a clinical diagnostic assay
for hereditary colon cancer that detects single nucleo-
tide, indel, and deletion/duplication mutations in MLH1,
MSH2, MSH6, PMS2, EPCAM, APC, and MUTYH. The
ColoSeq assay can be performed for approximately the
same cost as performing sequencing and deletion/dupli-
cation analysis of a single gene by traditional methods,
and with equivalent or better sensitivity and accuracy,
eliminating the need for stepwise molecular genetic test-
ing in patients with suspected Lynch or polyposis
syndromes.
Materials and Methods
DNA Samples
We tested a total of 82 unique DNA samples, including 23
peripheral blood DNA samples from patients with known
mutations in MLH1, MSH2, MSH6, PMS2, EPCAM, APC,
or MUTYH; 31 peripheral blood DNA samples from pa-
tients with a clinical history suggestive of Lynch or pol-
yposis syndrome; 19 peripheral blood DNA samples from
patients without a known family history of cancer; 6 pub-
licly available DNA samples from the HapMap project;15
and 3 DNA samples from colon cancer cell lines known to
harbor mutations in MMR genes and/or APC. Tumor cell
lines (LoVo, HCT116, LS174T) were obtained from WilliamM. Grady (University of Washington). HapMap samples
(NA18507, NA18558, NA07019, NA07348, NA10857,
NA10851) were obtained from Coriell Cell Repositories
(Camden, New Jersey). Clinical specimens were obtained
in accordance with the Declaration of Helsinki and the study
was approved by the Human Subjects Division of the Uni-
versity of Washington (protocol 34173) and the University of
Chicago Institutional Review Board.
Library Construction, Gene Capture, and
Massively Parallel Sequencing
Three micrograms of DNA was sonicated to a peak of 200
bp on a Covaris S2 instrument (Covaris, Woburn, MA) in
1 low TE (10 mmol/L Tris/0.1 mmol/L EDTA) for 6 min-
utes using frequency sweeping mode with duty cycle,
10%; intensity, 5; cycles per burst, 200 at a temperature
4° to 7°C. After sonication, DNA was purified with AMPure
XP beads (Beckman Coulter, Brea CA) and subjected to
three enzymatic steps: end repair, A-tailing, and ligation
to Illumina paired-end adapters as described in the Sure-
SelectXT Target Enrichment for Illumina multiplexed se-
quencing that is available for free download. All liquid
handling steps were performed in 96-well plates on a
Bravo liquid-handling instrument (Agilent Technologies,
Santa Clara, CA). The adapter-ligated library was ampli-
fied by polymerase chain reaction (PCR) for five cycles
with Illumina primers 1.0 and 2.0 and quantified by a
DNA1000 chip on a Bioanalyzer 2100 instrument (Agilent
Technologies). Individual paired-end libraries (500 ng)
were hybridized to a custom design of complementary
RNA (cRNA) biotinylated oligonucleotides targeting 31
genes in 30 genomic regions (see Supplemental Table
S1 at http://jmd.amjpathol.org). The 120-mer oligonucleo-
tide baits were designed in Agilent’s eArray web portal
with the following parameters: centered tiling, 3x bait
overlap and a maximum overlap of 20 bp into repetitive
regions. The custom design targets a total of 1.1 Mb of
DNA including 209 kb in MLH1, MSH2, MSH6, PMS2,
EPCAM, APC, and MUTYH (Table 1). The BED file of
probe sequences is available on request. After 24 hours
of hybridization at 65°C, the library-bait hybrids were
purified by incubation with streptavidin-bound T1 Dyna-
beads (LifeTechnologies, Carlsbad CA) and washed with
increasing stringency to remove nonspecific binding. Af-
Table 1. Genes Validated for ColoSeq
Gene Chromosome
Kb
targeted*
Genomic region
targeted (Hg 19)
Start End
MLH1 3 35 37029979 37097337
MSH2  EPCAM 2 48 47595263 47715360
MSH6 2 19 48005221 48039092
PMS2 7 17 6007870 6053737
APC 5 77 112038202 112186936
MUTYH 1 14 45789914 45811142
A total of 30 genomic regions representing 31 genes related to hered-
itary cancer risk were targeted19, but here we focus on validation of these
7 genes.
*Repetitive DNA elements were not targeted.
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the Dynabeads for 13 cycles with primers containing a
unique 6-bp index (Table 2). After PCR amplification, the
libraries were quantified by a high-sensitivity chip on a
Bioanalyzer 2100 instrument (Agilent Technologies).
Equimolar concentrations of 96 libraries were pooled to a
final concentration of 10 pM, denatured with 3N NaOH,
and cluster amplified with a cBot instrument on a single
lane of an Illumina v3 flow cell. Sequencing was per-
formed with 2  101-bp paired-end reads and a 7-bp
index read using SBS v3 chemistry on a HiSeq2000
(Illumina, Inc, San Diego, CA).
Mutation Analysis
Sequence alignment and variant calling were performed
against the reference human genome (UCSC hg19). Se-
quencing reads were aligned using MAQ,16 and SNVs
and insertions and deletions were detected as previously
described.12 Each variant was annotated with respect to
gene location and predicted function in Human Genome
Variation Society nomenclature. Deletions and duplications
of exons were detected by depth of coverage analysis.17 All
previously unidentified frameshift, nonsense, and splice site
mutations predicted to be deleterious to protein function
were confirmed by PCR amplification and Sanger sequenc-
ing. Exonic deletions and duplications were confirmed by
multiplex ligation-dependent probe amplification or gap-
PCR and direct sequencing.18
Results
ColoSeq Assay
The objective of our study was to evaluate the perfor-
mance of targeted DNA capture and massively parallel
Table 2. Postindex Barcodes
ATCACG AACAAA AATAGG ACTCTC
CGATGT CACGAT CCACGC CGGAAT
TTAGGC GATATA GCTCCA GTGGCC
TGACCA TATAAT TCGGCA TGCTGG
ACAGTG AACCCC ACAAAC ACTGAT
GCCAAT CACTCA CCCATG CTAGCT
CAGATC GATGCT GGCACA GTTTCG
ACTTGA TCATTC TCTACC TGGCGC
GATCAG AACTTG ACATCT AGAAGA
TAGCTT CAGGCG CCCCCT CTATAC
GGCTAC GCAAGG GGCCTG CGTACG
CTTGTA ATAATT ATCCTA ATGAGC
AAACAT AAGACT ACCCAG AGATAG
CAAAAG CATGGC CCGCAA CTCAGA
GAAACC GCACTT GTAGAG GAGTGG
TAATCG TCCCGA TGAATG TTCGAA
AAAGCA AAGCGA ACCGGC AGCATC
CAACTA CATTTT CCTTAG CTGCTG
GAATAA GCCGCG GTCCGC GGTAGC
TACAGC TCGAAG TGCCAT TTCTCC
AAATGC AAGGAC ACGATA AGCGCT
CACCGG CCAACA CGAGAA CCGTCC
GACGGA GCCTTA GTGAAA ATTCCT
AGGCCG ATACGG ATCTAT AGGTTTsequencing for the detection of inherited mutations incolon cancer in the clinical laboratory setting. We de-
signed oligonucleotides to target all exons, introns, and
approximately 10 kb of 5= and 3= flanking genomic re-
gions of the seven genes that are most commonly re-
sponsible for inherited risk of colon cancer (Table 1). Our
capture panel also includes 24 other genes that rarely
harbor mutations causing colon cancer, endometrial can-
cer, and other solid tumors,19 for a total of 31 captured
genes and 1.1 Mb of captured DNA after removal of
repetitive sequences. Here we focus on validation results
of the seven genes listed in Table 1 that constitute the
ColoSeq assay for Lynch and polyposis syndromes.
Workflow of the ColoSeq assay is summarized in Fig-
ure 1. We begin by fragmenting genomic DNA extracted
from peripheral blood and preparing libraries with an
average insert size of approximately 200 bp. ColoSeq
genes are captured via solution hybridization with com-
plementary oligonucleotide RNA (cRNA) baits (Agilent
SureSelect). Each captured sample library is amplified by
PCR to incorporate a unique index barcode, and up to 96
barcoded samples are pooled and run on a single lane of
an Illumina HiSeq2000 instrument.
It is unusual to pool patient samples in the clinical
setting because of the risks of sample misidentification
and analytic interference. To control for specimen mix-up
and for potential barcode-specific sequencing biases,
each clinical sample is indexed with two distinct bar-
codes and run in duplicate. Barcodes were selected
such that a single base change could not lead to one
barcode being misidentified as another (Table 2). Less
than 0.005% of sequencing reads were assigned to the
incorrect patient because of barcode misidentification.Figure 1. ColoSeq workflow.
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dian of 320-fold coverage per nucleotide across the en-
tire targeted region (range of median coverage between
samples 145-fold to 556-fold; Figure 2A). The median
coverage specifically across the seven ColoSeq genes is
475-fold (Figure 2B). Raw sequence of 0.3 gigabases
(Gb) (range 0.15 to 0.56 Gb) of high-quality (Q30) se-
quence per sample is generated when the maximum 96
samples are pooled within a lane. On average, 62% of
sequence reads are on target, mapping specifically to
the captured regions. We align sequences to the refer-
ence genome (build Hg 19) and select variants for further
analysis that meet the following criteria: i) variant is pres-
ent in sequence reads from both strands (mean  SD,
433 97 variants/sample), ii) population frequency of the
variant is less than 5% (44  31 variants/sample remain),
and iii) variant represents at least 5% of the sequence
reads at a particular site (26  21 variants/sample re-
main). We chose a threshold of 5% variant reads to en-
sure that variants in highly segmentally duplicated re-
gions of genes would be detected. Frequencies of
variants among individuals without colon cancer are
based on an internal database of more than 1000 unique
patients from different ethnic backgrounds who have had
targeted capture and massively parallel sequencing per-
formed for these genes.12,19 By using an internal fre-
quency database, we can quickly filter out both common
benign variants and potential recurrent artifactual variant
calls, leaving an average of 20 noncoding and only 6 rare
coding or splice junction variants per patient across the
seven genes. These filtered variants are then compared
with the exome variant server (NHLBI Exome Sequencing
Project [ESP], Seattle, WA), dbSNP, and public mutation
databases such as InSight20 (http://www.insight-group.org/
mutations) and results reviewed by a laboratory director.
Novel variants of uncertain significance (VUS) are analyzed by
PolyPhen2,21 SIFT,22 and MutationTaster23 to predict poten-
tial deleterious effects and are assessed for evolutionary
conservation. Pathogenicmutations and VUS are confirmed
by Sanger sequencing or multiplex ligation-dependent
probe amplification (for deletions/duplications). Missense
variants that are not well characterized are reported as VUS
when they meet the following criteria: i) population fre-quency 5%, ii) evolutionarily conserved, iii) predicted to
be at least possibly damaging by in silico prediction tools,
and iv) confirmed by Sanger sequencing.
Sensitivity
To assess the sensitivity of the ColoSeq assay to detect
pathogenic mutations, we blindly tested peripheral blood
DNA samples from 23 cancer patients and 3 colon cancer
cell lines (LS174T, HCT116, LoVo) with previously defined
germline mutations inMLH1,MSH2,MSH6, PMS2, EPCAM,
MUTYH, or APC. Some cell lines harbored more than one
mutation. ColoSeq correctly identified all mutations (23/23
patient mutations, 5/5 cell line mutations, 100% sensitivity)
including nonsense, missense, frameshift, in-frame dele-
tions, splice site, and large deletions and duplications
(Table 3, cohorts: known and cell line).24–39
To assess the analytic sensitivity of detecting all
heterozygous single base pair variants across these
genes, we evaluated six DNA samples that had been
genotypedby theHapMapProject15 (http://www.hapmap.
org, last accessed December 6, 2011). HapMap geno-
type data were available for a total of 1388 sites in ag-
gregate across the six samples, including 226
heterozygous SNVs (38  23 per sample), 144 homozy-
gous variants (27  15 per sample), and 1018 sites that
matched the reference genome (wild type, 170  23 per
sample). We focused on defining the sensitivity of heterozy-
gous variant detection because pathogenic mutations in
Lynch and polyposis syndromes are almost always heterozy-
gous, except inMUTYH. ColoSeq identified 222/226 heterozy-
gous SNVs in the seven genes captured by the assay. Two of
the four discrepant variantswere foundbySanger sequencing
to be errors in the HapMap annotation, for a sensitivity of
99.4% (222/224) (Table 4). The twoHapMapvariants thatwere
missed by ColoSeq corresponded to a single intronic SNV
(rs3771280) that was missed in two different samples. This
SNV is in close proximity to two other SNVs (rs3771278,
rs3771279), which were both either heterozygous or homozy-
gous for the rarer allele in the two samples, resulting in the
reads mapping to this region being discarded because of
poor alignment with the reference genome. ColoSeq correctly
Figure 2. Depth of coverage. Depth of cover-
age from a representative patient sample run on
a single lane of a HiSeq2000 instrument in a
96-plexed ColoSeq run. A: Distribution of cov-
erage for each targeted base. Each bar represents
the number of base pairs (in 1000s) at a partic-
ular depth of coverage. Of the targeted bases,
98.5% have a minimum of 50-fold coverage. B:
Median coverage across each ColoSeq gene is
shown (average coverage of 475-fold). Areas
with depth of coverage 1000-fold reflect cap-
ture of highly homologous genomic regions.identified all HapMap variants within exons and splice junc-
c.1145G
hich we
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were correctly identified except rs3771280.
We next evaluated the performance of ColoSeq in a
cohort of 31 prospectively collected blood samples from
patients with a clinical history suggestive of Lynch or
polyposis syndrome, but without a previously determined
mutation. In this cohort, we identified six patients with
pathogenic mutations and three additional patients with
VUS; the mutations were all confirmed using alternative
Table 3. Mutations and Variants of Uncertain Significance Identi
Cohort ID Gene Mutation/VUS†
Cell line HCT116 MLH1 c.755CA20 S2
Cell line LoVo APC c.3340CT24,25 R1
Cell line LoVo APC c.4289delC25 M1
Cell line LoVo MSH2 51kb deletion26 de
Cell line LS174T MLH1 c.350CT27 T11
Known FO5 MSH2 31kb deletion28 de
Known 011 MSH2 c.513delG29 K1
Known 012 MSH6 c.3103CT30 R1
Known 013 MSH2 c.1609AT K5
Known 014 MLH1 c.1668-1GA28 Sp
Known 017 MLH1 c.1517 TC31 V5
Known 022 APC c.221-2AG Sp
Known 023 MLH1 c.1381AT32 K4
Known 025 MSH2 c.380AG N1
Known 031 MSH6 c.694CT Q2
Known 032 MSH2 
EPCAM
40kb deletion de
E
Known 034 MSH2 c.2501_2507delCTAATTT N8
Known 035 PMS2 c.1927CT33 Q6
Known 037 MLH1 18kb duplication du
Known 086 MSH6 c.3485_3487delCTG34 A1
Known 087 MSH2 20kb deletion de
Known 088 MSH6 c.3956_3959delAAGC34 A1
Known 090 MSH6 c.2731CT34 R9
Known 093 MSH6 c.2731CT34 R9
Known 094 MSH6 c.3939_3940ins1934 Q1
Known 096 MLH1 3kb deletion35 de
Known 147 MUTYH c.1187CT36 G3
Known 148 MUTYH c.1187CT36 G3
Control 047 MLH1 c.2161TC Y7
Control 063 MLH1 c.1151TA31 V3
Unknown 003 APC c.1959GA37 ?Sp
Unknown 004 MSH6 c.2147_2150delCAGT V7
Unknown 006 APC c.426_427delAT38 L14
Unknown 018 MUTYH c.158-1GA Sp
Unknown 036 PMS2 c.2192_2196delTAACT39 L73
Unknown 089 PMS2 c.2192_2196delTAACT39 L73
Unknown 040A MSH6 c.2588AG E8
Unknown 041 APC c.646CT38 R2
Unknown 080 PMS2 3.3kb deletion de
Chr, chromosome; NA, not applicable.
Note: Asterisk (*) refers to stop codon (per Human Genome Variation
†Reference sequences: MLH1 NM_000249.3; MSH2 NM_000251.
NM_000038.5; MUTYH NM_001128425.1.
‡Numbers reflect perfect matches only. For CNVs, total reads refers t
§This mutation is commonly referred to as G382D (NM_001048171.1:
¶Exact breakpoints were determined for the PMS2 exon 8 deletion, w
Table 4. Analytic Sensitivity, Specificity, and Accuracy
Sensitivity
All variants (with introns) 99.4% (222/224)
Exons only 100% (27/27)Calculations are based on heterozygous variant detection in 6 HapMap sammethods (Table 3; cohort: unknown). Most of the patients
in this cohort had previous clinical testing performed by
outside laboratories for one or more of the ColoSeq
genes, with negative results. Even though the group was
enriched for patients who had negative test results for
one or more of the ColoSeq genes, our mutation detec-
tion in 6 of 31 patients was similar to published rates
among patients meeting Bethesda criteria,40 highlighting
the utility of a comprehensive Lynch and polyposis panel.
ColoSeq
ct Chr Start (Hg19) End (Hg19)
Total
reads‡
Variant
reads‡
3 37,056,000 244 244
5 112,174,631 417 194
*42 5 112,175,580 112,175,581 174 97
3-8 2 47,637,277 47,688,664 NA NA
3 37,045,935 325 323
6 2 47,688,689 47,719,344 322 160
2 2 47,637,378 47,637,379 64 31
2 48,028,225 389 117
2 47,693,895 151 73
3 37,083,758 180 91
3 37,070,382 227 114
5 112,102,884 143 80
3 37,067,470 139 75
US) 2 47,637,246 64 35
2 48,025,816 152 76
 2 47,595,376 47,635,837 322 172
2 47,707,877 47,707,884 129 47
7 6026,469 97 48
12 3 37,050,170 37,067,982 351 509
2 48,032,092 48,032,095 134 58
1-6 2 47,629,721 47,649,842 274 120
*6 2 48,033,745 48,033,749 174 72
2 48,027,853 130 61
2 48,027,853 74 41
*5 2 48,033,728 48,033,728 166 20
14-15 3 37,081,516 37,084,593 345 177
1 45797228 147 68
1 45797228 102 32
US) 3 37,092,034 220 137
US) 3 37,067,240 167 77
US) 5 112,173,250 199 92
8 2 48,027,269 48,027,273 100 41
5 112,111,329 112,111,331 143 66
S) 1 45,799,276 61 33
7 6018,306 6018,311 255 64
7 6018,306 6018,311 545 81
US) 2 48,027,710 278 140
5 112,128,143 179 83
8 7 6033,256¶ 6036,607¶ 409 192
standard nomenclature).
6 NM_000179.2; PMS2 NM_000535.5; EPCAM NM_002354.2; APC
rmalized read depth and variant reads to the read depth in the sample.
A).
detected in patient 080.
Specificity Accuracy
99.4% (1012/1018) 99.4% (1234/1242)
100% (198/198) 100% (225/225)fied by
Effe
52*
114*
431Cfs
l exons
7M
l ex 9-1
72Afs*
035*
37*
lice
06A
lice
61*
27S (V
32*
l ex 1-2
PCAM
35Lfs*4
43*
p ex 6-
162del
l exon
320Gfs
11*
11*
314Sfs
l exon
96D§
96D§
21H (V
84D (V
lice (V
17Afs*1
3Afs*4
lice (VU
1Cfs*3
1Cfs*3
63G (V
16*
l exon
Society
1; MSH
o the noples.
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We determined analytic specificity by analyzing the 6
HapMap characterized samples at 1018 known nonvari-
ant (reference sequence) sites in the seven ColoSeq
genes. ColoSeq correctly identified 1012/1018 sites as
nonvariant from the reference genome for an analytic
specificity of 99.4% (Table 4). The six false-positive vari-
ants that we detected but that were not reported as
present in HapMap samples were in MLH1 intron 11
(rs3774339, detected in one sample), and in segmentally
duplicated exons 11 and 14 of PMS2 (rs1805321, de-
tected in three samples; rs1059060, detected in two sam-
ples). Analytic specificity was 100% within single-copy
exons and splice junctions (198/198). We calculated an-
alytic accuracy as [number of true positives  number of
true negatives]/[total number of HapMap genotyped
sites]. Accuracy was 99.4% and 100% for all variants and
exons only, respectively (Table 4).
To assess clinical specificity we selected 19 control
patients without a personal or family history of colon can-
cer or other Lynch syndrome–associated cancers. Pa-
tients were selected to represent diverse ethnic back-
grounds including African American, Pacific Islander,
white, Indian, Cambodian, Vietnamese, Iranian, Hispanic,
Alaskan Native, Chinese, Laotian, and Filipino (see Sup-
plemental Table S2 at http://jmd.amjpathol.org). We did
not find any pathogenic mutations in this cohort, for a spec-
ificity of 100% (19/19). However, we identified a VUS that
met our criteria for clinical reporting in two control samples;
one each from an African-American and a Vietnamese con-
trol subject (Table 3, cohort: control), suggesting that about
10% of nonwhite patients without Lynch or polyposis syn-
dromes will have a VUS detected (2/17).
Deletion/Duplication Analysis
The very high fold coverage (mean, 320-fold) allowed
accurate detection of large deletions and duplications
using normalized depth of coverage and split-read anal-
ysis (Figure 3).12,17 Exact breakpoints could not be de-
termined for most large deletions and duplications be-
cause breakpoints are commonly in Alu or other repetitive
DNA elements that are not captured by our design. How-
ever, the assay demonstrated at least exon-level resolu-
tion for all large deletions and duplications in all cases,
which was comparable or better than the resolution of
traditional approaches to deletion/duplication analysis
such as multiplex ligation-dependent probe amplifica-
tion. ColoSeq correctly identified 6/6 known large dele-
tions/duplications in blinded challenge specimens (Table
3, cohort: known). In addition, in DNA from a patient with
microsatellite instability–positive endometrial cancer and
isolated loss of PMS2 protein expression (by IHC) who
had not had previous genetic testing, we detected a
PMS2 exon 8 deletion. We confirmed the exact break-
points of this mutation by gap-PCR and Sanger sequenc-
ing (Table 3, patient 080).Reproducibility and Cutoff
To determine the between-run assay reproducibility, we
ran 75 samples on at least two independent runs. We
detected 39/39 pathogenic mutations and VUS (Table 3)
in replicate runs, yielding 100% between-run reproduc-
ibility of mutation detection. We next assessed the be-
tween-run reproducibility for all variant calls in unique
exons and splice junctions (exons only, mean  39  9
variants per sample), or for the entire captured region,
including deeply intronic, nonunique, and repetitive DNA
elements (with introns, mean  451  70 variants per
sample). We separated SNVs and indel variants for this
analysis. Not surprisingly, assay reproducibility in-
creased as a function of the number of variant sequence
reads, particularly for indel variants (Figure 4). We se-
lected a minimum threshold of 15 variant sequencing
reads to assess assay reproducibility based on the fol-
lowing two criteria: all pathogenic mutations and VUS
were reliably detected with at least 15 variant reads, and
the threshold of 15 variant reads substantially improved
assay reproducibility without sacrificing sensitivity (all de-
tected HapMap variants had at least 15 reads). We did
not use receiver operating characteristic analysis to se-
lect the cutoff because the analytic specificity was 99%
at all cutoff values (based on the 1018 HapMap known
wild-type SNVs) (see Supplemental Figure S1 at http://
jmd.amjpathol.org). For exons only, for which the perfor-
mance of the assay is most critical, between-run repro-
ducibility was 99.3% for SNVs and 98.9% for indels at a
cutoff of 15 variant reads (Figure 4). Reproducibility im-
proved to 100% for indels and SNVs at cutoff values
higher than 40, which is representative of the majority of
variant calls (66% of indels and 86% of SNVs had 40 or
more variant reads). Reproducibility was lower with in-
trons, at 93.9% for SNVs and 92.5% for indels at the cutoff
of 15 reads (see Supplemental Figure S2 at http://jmd.
amjpathol.org). Variant calls that did not replicate on re-
peated runs were most prevalent in introns of PMS2,
which has a family of highly homologous pseudogenes
on chromosome 7.41 Importantly, we were able to repro-
ducibly detect all SNV, indel, and deletion mutations in
exons of PMS2, even in regions of the gene that are
segmentally duplicated (Table 3).
Within-run reproducibility was determined by running
12 samples in duplicate on the same run. The within-run
reproducibility for exons only was 100% for both SNVs
and indels at the cutoff of 15 reads (Figure 4). Within-run
reproducibility with introns was 95.0% for SNVs and
92.1% for indels at the cutoff of 15 variant reads, which
was qualitatively similar to the between-run results (see
Supplemental Figure S2 at http://jmd.amjpathol.org).
Discussion
Next-generation sequencing technology is rapidly chang-
ing the landscape of genetic testing. During a plenary ses-
sion at the 2011 Association of Molecular Pathology annual
meeting, Dr. Stephen Kingsmore suggested that molecular
pathologists will look back to this time as a golden age in the
ss adjac
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JMD July 2012, Vol. 14, No. 4field of molecular diagnostics because of the new possi-
bilities afforded by massively parallel sequencing. Much
of the excitement surrounding this technology is directed
at the possibility of clinical exome and whole-genome
sequencing as a one-stop, all-inclusive genetic test. Clin-
ical laboratories such as Ambry Genetics and Baylor
Whole Genome Laboratory are already offering exome
sequencing.42,43 However, exome and genome se-
quencing currently have important limitations compared
with targeted approaches with regard to both cost-effec-
Figure 3. Deletions and duplications detected by normalized depth of cover
PMS2 exon 8) and one example of a genomic duplication (MLH1 exons 6-1
Significant deviations less than or greater than a normalized ratio of 1 acro
Genomic coordinates shown on the x axis are hg19.tiveness and analytic performance in the clinical setting.Exome sequencing often does not achieve adequate
depth of coverage to detect structural rearrangements
such as large deletions and duplications that are a sig-
nificant component of the mutational spectrum for many
inherited disorders. Considering that up to 15% of dis-
ease-causing mutations in the Lynch syndrome are due
to large deletions,2 it is clinically relevant if this class of
mutation is missed. An important advantage of the targeted
approach we have taken with ColoSeq is that it can readily
detect structural rearrangements through a very high depth
ee examples of genomic deletions (MLH1 exons 14-15, MSH2 exons 1-6, and
ted by ColoSeq. Read depth is normalized across the 96 samples on a run.
ent baited regions reflect genomic deletions (red) and duplications (blue).age. Thr
2) detecof coverage.
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proach for clinical diagnostic testing include the follow-
ing: i) For scalability, we were able to multiplex and pool
96 index barcoded samples onto one lane of an Illumina
HiSeq flow cell, facilitating cost-effectiveness and allow-
ing samples to be run in duplicate to control for sample
mix-up and analytic variability. ii) Clinical validity was
achieved by targeting and validating only genes that,
when mutated, are well-established causes of hereditary
colon cancer; it is therefore straightforward to incorporate
the results of ColoSeq testing into clinical decision-mak-
ing. iii) Limiting VUS, which can cause stress for both
patients and providers, was achieved by our focus on a
relatively limited number of genes and the existence of
well-annotated hereditary colon cancer mutation data-
bases such as InSight,20 and MMRUV44; we found a
reportable VUS in only about 1 in 10 patients. iv) Clinical
expertise is strengthened by focusing on just a handful of
genes, making it reasonable for a molecular pathologist
to gain familiarity with their mutational spectrum and to
consider the data at each variant position individually
before signing out a case.
At least one previous study has evaluated targeted
capture and massively parallel sequencing for the detec-
tion of Lynch and polyposis syndromes.45 In that study,
solid-phase NimbleGen 385K Custom Sequence Capture
Arrays were used to examine 22 genes that included
MLH1, MSH2, MSH6, and APC. One of four samples with
a known Lynch syndrome indel mutations was missed
using both Roche 454 (Roche, Branford, CT) and Illumina
GAII technology, along with many other neutral variants
that were detectable by Sanger sequencing. The reason
for the relatively poor performance could be attributed to
inefficient/off-target capture, limitations in sequencing
homopolymer regions on the 454 platform, and difficulties
calling indels on the Illumina GAII platform due to short
(36 bp) single-end read length. Both gene capture and
sequencing technology has matured in the past 2 years,
allowing us to overcome these limitations through more
efficient capture and much longer 101-bp paired-end
reads.Methods and guidelines to rigorously validate clinical
diagnostic assays using next-generation sequencing
technology are just beginning to emerge. The Associa-
tion of Molecular Pathology is leading an effort to estab-
lish formal guidelines for the validation of tests using this
technology. This includes a statement from the Associa-
tion of Molecular Pathology in June 2011 that outlines
aspects of method validation and ongoing quality control,
including sensitivity and specificity, and recommends
that precharacterized control samples such as HapMap
DNAs be analyzed on each run (http://www.amp.org/
documents/AMPCommentsNGS_June2011_Final.pdf,
last accessed December 1, 2011). Additional groups
such as the Centers for Disease Control–led Nex-StoCT
working group (http://www.cdc.gov/osels/lspppo/
Genetic_Testing_Quality_Practices/Nex-StoCT.html, last
accessed December 1, 2011) and the College of Amer-
ican Pathologists are also working to establish guide-
lines. We have taken a multifaceted approach to validate
the ColoSeq assay that includes measurements of both
analytic and clinical sensitivity and specificity, between-
and within-run reproducibility, and selection of cutoffs
(analytic measurement range). In addition to using
blinded challenge specimens with defined mutations at a
single locus, we determined analytic sensitivity using
HapMap samples that had between 50 and 100 defined
variants each in the seven ColoSeq genes. Through this
process, we discovered a false-negative intronic SNV
(rs3771280) and, importantly, were alerted to the mech-
anism by which this SNV was missed.
We were particularly concerned with defining the VUS
detection rate of the assay, given the large amount of
DNA sequenced and the potential consequence that the
assay would cause undue worry among patients and
their families if a high number of VUS were reported. We
were pleased to find a reportable VUS for only two non-
white patients of 19 patients without Lynch or polyposis
syndrome, even among patients of diverse ethnic back-
grounds in which missense variants are not well charac-
terized. Still, we will undoubtedly encounter VUS more
Figure 4. Between-run and within-run repro-
ducibility. Between-run and within-run repro-
ducibility are shown as a function of minimum
threshold for indel variants and calling single
nucleotide (SNV). Variants were considered re-
producible if they met or exceeded the specified
cutoff value in the index sample and appeared in
the replicate sample regardless of cutoff value.
Reproducibility is shown for all variants in sin-
gle-copy regions of exons and splice junctions.
A threshold of 15 variant reads was chosen for
the assay. Black squares, between-run; grey cir-
cles, within run.frequently than in standard single-gene assays. Better in
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be valuable, such as gene-specific algorithms46 and ag-
gregate pathogenicity scores47 that can integrate estab-
lished algorithms such as PolyPhen2,21 SIFT,22 Genomic
Evolutionary Rate Profiling,48 and MutationTaster.23
We designed the seven-gene ColoSeq panel to be
focused only on genes that have a well-established role
in clinical decision making for patients with Lynch or
polyposis syndromes. Mutations in genes such as MLH3,
MSH3, PMS1, and EXO1 that have been reported to
cause Lynch syndrome in rare cases2 are not included in
the ColoSeq panel because of lack of knowledge regard-
ing their clinical significance. Our design targets addi-
tional genes for rare hereditary cancer syndromes that
may predispose to gastrointestinal cancers, including
Cowden syndrome (PTEN), hereditary diffuse gastric
cancer (CDH1), Peutz-Jeghers syndrome (STK11), and
Li-Fraumeni syndrome (TP53), and we are optimistic
about validating these genes in a future expanded ver-
sion of the ColoSeq panel.
A limitation of the assay is the long turnaround time ne-
cessitated by the 9-day run time on the HiSeq2000 instru-
ment. ColoSeq is amenable to transition to a smaller, more
clinically oriented instrument, with faster turnaround time
such as the MiSeq (Illumina) or Ion Torrent (Guilford, CT).
However, an important drawback of these more rapid in-
struments is that only about 1 to 2 Gb of sequence data are
generated per run, compared with 30 to 40 Gb for a single
lane of a HiSeq2000. We estimate that only about three to
five index barcoded samples could be pooled per run on
the MiSeq using 100-bp or 150-bp paired-end reads to
achieve the same depth of coverage as our current 96-
plexed assay on the HiSeq2000. The assay workflow and
turnaround time might also be improved through newer,
more streamlined library preparation strategies such as
transposase-based methods.49
In conclusion, we have developed and validated a
comprehensive and cost-effective test for hereditary co-
lon cancer syndromes that uses solution-based targeted
capture and next-generation sequencing. The assay de-
tected 100% of known mutations in challenge specimens,
including all indel mutations and large deletions and du-
plications. We believe that ColoSeq will streamline and
simplify genetic testing in patients with suspected hered-
itary colon cancer syndromes, sparing patients from
needing to have multiple rounds of expensive genetic
testing to establish a diagnosis.
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